Sandhill Capital Partners LLC Has $30.65 Million Stock Holdings in Danaher Corporation $DHR

Key Points

• Sandhill Capital Partners LLC increased its stake in Danaher Corporation by 51.7%, owning 149,486 shares valued at approximately $30.65 million.
• Danaher reported earnings per share of $1.80 for the latest quarter, exceeding estimates and showing a 3.4% year-over-year revenue growth.
• The stock has been subject to multiple price target adjustments by analysts, with a consensus rating of "Moderate Buy" and an average price target of $247.61.

Sandhill Capital Partners LLC raised its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 51.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,486 shares of the conglomerate's stock after buying an additional 50,966 shares during the quarter. Danaher accounts for about 2.5% of Sandhill Capital Partners LLC's investment portfolio, making the stock its 19th largest position. Sandhill Capital Partners LLC's holdings in Danaher were worth $30,645,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nuveen LLC bought a new position in shares of Danaher during the 1st quarter worth about $833,941,000. GAMMA Investing LLC increased its stake in Danaher by 24,958.2% during the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after acquiring an additional 1,863,381 shares during the period. Two Sigma Advisers LP lifted its position in shares of Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after acquiring an additional 1,601,800 shares during the period. Invesco Ltd. grew its holdings in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Danaher by 460.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after acquiring an additional 1,107,998 shares during the period. Institutional investors own 79.05% of the company's stock.

Danaher Trading Up 1.5%

Danaher stock opened at $212.2350 on Wednesday. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The company has a market cap of $151.97 billion, a price-to-earnings ratio of 45.16, a P/E/G ratio of 2.92 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm has a 50-day moving average of $200.33 and a 200-day moving average of $199.54.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on DHR shares. Barclays reaffirmed an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. JPMorgan Chase & Co. decreased their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Argus decreased their price objective on Danaher from $260.00 to $240.00 in a research report on Wednesday, April 23rd. Finally, Wells Fargo & Company dropped their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.